BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29168038)

  • 1. Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
    Soyama H; Miyamoto M; Takano M; Aoyama T; Matsuura H; Sakamoto T; Takasaki K; Kuwahara M; Kato K; Yoshikawa T; Iwahashi H; Tsuda H; Furuya K
    Med Oncol; 2017 Nov; 34(12):201. PubMed ID: 29168038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.
    Miyamoto M; Takano M; Iwaya K; Shinomiya N; Goto T; Kato M; Suzuki A; Aoyama T; Hirata J; Nagaoka I; Tsuda H; Furuya K
    Br J Cancer; 2015 Feb; 112(4):739-44. PubMed ID: 25628093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    Yamamoto K; Kikuchi Y; Kudoh K; Nagata I
    J Cancer Res Clin Oncol; 2000 Mar; 126(3):168-72. PubMed ID: 10741911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
    Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
    Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line.
    Hata K; Osaki M; Kanasaki H; Nakayama K; Fujiwaki R; Ito H; Miyazaki K
    Anticancer Res; 2003; 23(2B):1525-31. PubMed ID: 12820419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUS81 is associated with cell proliferation and cisplatin sensitivity in serous ovarian cancer.
    Xie S; Zheng H; Wen X; Sun J; Wang Y; Gao X; Guo L; Lu R
    Biochem Biophys Res Commun; 2016 Aug; 476(4):493-500. PubMed ID: 27255997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
    Wan B; Dai L; Wang L; Zhang Y; Huang H; Qian G; Yu T
    Endocr Relat Cancer; 2018 Jan; 25(1):69-82. PubMed ID: 29066501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
    Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
    Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
    Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
    Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin.
    Kobayashi Y; Seino K; Hosonuma S; Ohara T; Itamochi H; Isonishi S; Kita T; Wada H; Kojo S; Kiguchi K
    Gynecol Oncol; 2011 May; 121(2):390-4. PubMed ID: 21272926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrin αII and βII tetramers contribute to platinum anticancer drug resistance in ovarian serous adenocarcinoma.
    Maeda O; Shibata K; Hosono S; Fujiwara S; Kajiyama H; Ino K; Nawa A; Tamakoshi K; Kikkawa F
    Int J Cancer; 2012 Jan; 130(1):113-21. PubMed ID: 21328338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
    Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
    Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
    Yamaguchi N; Mimoto R; Yanaihara N; Imawari Y; Hirooka S; Okamoto A; Yoshida K
    Tumour Biol; 2015 Aug; 36(8):5913-23. PubMed ID: 25712377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Akeshima R; Sato S; Kamazawa S; Takahashi M; Kanamori Y; Suzuki M; Ohwada M; Terakawa N
    Oncology; 2002; 62(4):349-53. PubMed ID: 12138243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R; Nardinocchi L; Pistritto G; D'Orazi G
    Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells.
    Laatio L; Myllynen P; Serpi R; Rysä J; Ilves M; Lappi-Blanco E; Ruskoaho H; Vähäkangas K; Puistola U
    Tumour Biol; 2011 Oct; 32(5):985-95. PubMed ID: 21674241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
    Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
    Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.